Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany

References

• World Health Organization. Prevention of cardiovascular disease: guideline for assessment and management of cardiovascular risk. 2007. Available at http://www.who.int/cardiovascular_diseases/guidelines/Full%20text.pdf [Last accessed on November 2nd, 2011]
   Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
   PubMed Web of Science ®Google Scholar
• Prugger C, Heuschmann PU, Keil U. Epidemiologie der hypertonie in Deutschland und weltweit. Herz 2006;31:287-93
   Google Scholar
• Wille E, Scholze J, Alegria E, et al. Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur J Health Econ 2011;12:205-18
   Google Scholar
• Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006;24:215-33
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308-47
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Lacourciere Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009;54:32-9
   PubMed Web of Science ®Google Scholar
• Fox JC, Leight K, Sutradhar SC, et al. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich) 2004;6:437-42
   PubMedGoogle Scholar
• Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16:80-6
   PubMed Web of Science ®Google Scholar
• Neutel JM. Fixed combination antihypertensive therapy. In: Oparil S, Weber MA, eds. Hypertension: a companion to Brenner and Rector's the Kidney. 2nd edn. Philadelphia, PA: Elsevier, 2005. p 522-9
   Google Scholar
• Neutel JM, Smith DH, Weber MA, et al. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich) 2005;7:641-6
   PubMedGoogle Scholar
• Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008;24:2389-401
   PubMed Web of Science ®Google Scholar
• Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007;9:355-64
   PubMedGoogle Scholar
• Mancia G, De BG, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007;25:1751-62
   PubMed Web of Science ®Google Scholar
• Deutsche Hochdruckliga e.V. DHL®. Deutsche Gesellschaft für Hypertonie und Prävention. Leitlinien zur Behandlung der arteriellen Hypertonie. 2008. Available at http://www.awmf.org/uploads/tx_szleitlinien/046-001_S2_Behandlung_der_arteriellen_Hypertonie_06-2008_06-2013.pdf [Last accessed November 2, 2011]
   Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-9
   PubMed Web of Science ®Google Scholar
• Brixner DI, Jackson KC, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin 2008;24:2597-607
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
   PubMed Web of Science ®Google Scholar
• Jackson KC, Sheng X, Nelson RE, et al. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther 2008;30:1558-63
   PubMed Web of Science ®Google Scholar
• Sicras Mainar A, Galera Llorca J, Muñoz Ortí G, et al.. Influence of compliance on the incidence of cardiovascular events and health costs when using single-pill fixed-dose combinations for the treatment of hypertension. Med Clin (Barc) 2011;136:183-91
   PubMed Web of Science ®Google Scholar
• Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 2010;26:2065-76
   PubMed Web of Science ®Google Scholar
• Zeng F, Patel BV, Andrews L, et al. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin 2010;26:2877-87
   PubMed Web of Science ®Google Scholar
• Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005;14:795-803
   PubMed Web of Science ®Google Scholar
• Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75
   PubMed Web of Science ®Google Scholar
• Hasford J, Schroder-Bernhardi D, Rottenkolber M, et al. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol 2007;63:1055-61
   PubMed Web of Science ®Google Scholar
• Patel BV, Remigio-Baker RA, Mehta D, et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich) 2007;9:692-700
   PubMedGoogle Scholar
• Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment–a review. Cardiovasc Diabetol 2009;8:18
   PubMed Web of Science ®Google Scholar
• Hughes D, Cowell W, Koncz T, et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007;10:498-509
   PubMed Web of Science ®Google Scholar
• Destro M, Cagnoni F, D'Ospina A, et al. New strategies and drugs in the treatment of hypertension: monotherapy or combination? Recent Pat Cardiovasc Drug Discov 2010;5:69-81
   PubMedGoogle Scholar
• Erdine S. Compliance with the treatment of hypertension: the potential of combintation therapy. J Clin Hypertens (Greenwich) 2010;12:40-6
   PubMed Web of Science ®Google Scholar
• Patel BV, Remigio-Baker RA, Thiebaud P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract 2008;9:61
   PubMed Web of Science ®Google Scholar
• Schmieder RE. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm. Clin Exp Hypertens 2010;32:35-42
   PubMed Web of Science ®Google Scholar
• Schrader J, Bramlage P, Luders S, et al. BP goal achievement in patients with uncontrolled hypertension: results of the treat-to-target post-marketing survey with irbesartan. Clin Drug Investig 2007;27:783-96
   PubMed Web of Science ®Google Scholar
• Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009;47:617-26
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16
   PubMed Web of Science ®Google Scholar
• Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-86
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Schwertfeger M, Bramlage P. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. Vasc Health Risk Manag 2009;5:991-1000
   PubMedGoogle Scholar
• Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-81
   PubMed Web of Science ®Google Scholar
• Degli EE, Sturani A, Di MM, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002;16:439-44
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Plauschinat CA, Skrepnek GH, et al. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007;20:72-80
   PubMed Web of Science ®Google Scholar
• Hoer A, Gothe H, Khan ZM, et al. Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. J Hum Hypertens 2007;21:744-6
   PubMed Web of Science ®Google Scholar
• Mathes J, Kostev K, Gabriel A, et al. Relation of the first hypertension-associated event with medication, compliance and persistence in naive hypertensive patients after initiating monotherapy. Int J Clin Pharmacol Ther 2010;48:173-83
   PubMed Web of Science ®Google Scholar
• Jones DW, Hall JE. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure and evidence from new hypertension trials. Hypertension 2004;43:1-3
   PubMed Web of Science ®Google Scholar
• Hess G, Hill J, Lau H, et al. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. Pharmacy and Therapeutics 2008;33:652-66
   Google Scholar
• Maronde RF, Chan LS, Larsen FJ, et al. Underutilization of antihypertensive drugs and associated hospitalization. Med Care 1989;27:1159-66
   PubMed Web of Science ®Google Scholar
• Paramore LC, Halpern MT, Lapuerta P, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care 2001;7:389-98
   PubMed Web of Science ®Google Scholar
• Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446-57
   PubMed Web of Science ®Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
   PubMed Web of Science ®Google Scholar